Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Aug;26(4):427-39.
doi: 10.1016/j.bpobgyn.2012.01.010. Epub 2012 Mar 2.

Overview of microbicides for the prevention of human immunodeficiency virus

Salim S Abdool Karim  1 , Cheryl Baxter
Affiliations
Review

Overview of microbicides for the prevention of human immunodeficiency virus

Salim S Abdool Karim et al. Best Pract Res Clin Obstet Gynaecol. 2012 Aug.

Abstract

Human immunodeficiency virus (HIV) prevention tools that women can use and control are urgently needed. Microbicides are chemical products applied to the vagina or rectum to prevent the sexual transmission of HIV. Four classes of candidate microbicides have been tested to date: those that (1) enhance the natural defences in the vagina to inactivate HIV; (2) inactivate HIV in the vagina; (3) prevent HIV from attaching to, and fusing with, the host cells; and (4) prevent HIV from replicating in genital tract host cells. Despite numerous disappointing efficacy trial results over the past 20 years, substantial progress is now being made in microbicide development after the release of the CAPRISA 004 trial, which provided proof-of-concept that topical antiretroviral microbicides can prevent sexual transmission of HIV and herpes simplex type-2 infection. Microbicides, which fill an important gap for women-controlled prevention methods, have the potential to alter the course of the HIV pandemic.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Past and current microbicide effectiveness trials. Adapted with permission.
See this image and copyright information in PMC

References

    1. UNAIDS; WHO. Geneva: Joint United Nations Programme on HIV/AIDS and World Health Organisation; 2009. AIDS Epidemic Update.
    1. Pettifor AE, Rees HV, Kleinschmidt I, Steffenson AE, MacPhail C, Hlongwa-Madikizela L, et al. Young people's sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey. Aids. 2005;19:1525–1534. - PubMed
    1. Shisana O, Rehle T, Simbayi LC, Zuma K, Jooste S, Pillay-van-Wyk V, et al. South African national HIV prevalence, incidence, behaviour and communication survey 2008: A turning tide among teenagers? Cape Town: HSRC Press; 2009.
    1. Haynes BF, Shattock RJ. Critical issues in mucosal immunity for HIV-1 vaccine development. J Allergy Clin Immunol. 2008;122:3–9. - PMC - PubMed
    1. Yeaman GR, Asin S, Weldon S, Demian DJ, Collins JE, Gonzalez JL, et al. Chemokine receptor expression in the human ectocervix: implications for infection by the human immunodeficiency virus-type I. Immunology. 2004;113:524–533. - PMC - PubMed

MeSH terms